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ABSTRACT 
The study was aimed to have a conceptual review of the disease Madhumeha and its treatment in 
particular to the use of an herbal drug” Phalatrikadi Kwath” and to compare its efficacy with the 
control drug (metformin) and placebo through scientific parameters in a double blind clinical control 
trial. Madhumeha, also known as Diabetes Mellitus is one of the types of Vataja prameha, that has been 
considered as an incurable disease (Mahagada). Due to indulgence in etiological factors it results in 
the incomplete formation of Kapha and Meda which further proceeds downward through the channels 
of Mutravaha srotas and get localized at Basti mukha leading to the symptoms like Prabhoota mutrata 
(polyurea), Avila mutrata (tubidity of urine) etc. As the disease is Chirakari, it requires an effective 
treatment which can be continued for a long time without any ill effects. Among the many treatment 
measures mentioned, Phalatrikadi kwath has been selected in this study and the effect was evaluated. 
The clinical study includes 50 patients of either sex between 30-60 years of age with Madhumeha 
(Type2 Diabetes Mellitus) were recruited having range of blood sugar (fasting 126-180 mg/dl, 
postprandial sugar, 200-250 mg/dl) attending the OPD of G.A.M Puri, Odisha and were divided into 
three groups. Group I (30 patients) were treated with trial drug (Phalatrikadi kwatha), Group II (10 
patients) were treated with control drug (Metformin) and Group III (10 patients) were treated with 
placebo. All the three groups were recommended with uniform classically described diet (Ahara) & 
regimen (Vihara). Patients were evaluated in an interval of 15 days for one month. FBS, PPBS with 
clinical sign & symptoms were assayed. After evaluating the total effects of the treatment, it was 
observed that Phalatrikadi kwath along with diet and regimen gave satisfactory relief in comparison 
to control drug (metformin)which is an established drug. 
KEYWORDS: Madhumeha, Diabetes Mellitus, Diet, lifestyle, Ahara vihara, Phalatrikadi kwath. 
INTRODUCTION
 Madhumeha, from time immemorial is acting 
as a malady troubling the mankind till the present era 
and continues to increase in numbers and significance 
as it is a multifactorial disease develops due to 
abnormal interaction of Vata dominant Tridosha with 
ten Dusyas[1,2]. Changing lifestyles lead to reduced 
physical activity and increased obesity. Estimates of the 
current and future burden of diabetes are important to 
allocate community and health resources and to 
emphasize the role of lifestyles and encourage 
measures to counteract trends for increasing 
prevalence. Amongst the many dreadful conditions 
arising because of modern-day living, Madhumeha, a 
comparable condition of Diabetes Mellitus Diabetes 
Mellitus is a metabolic disorder in which carbohydrate 
utilization is reduced and that of lipid and protein 
enhanced due to deficiency of insulin characterized by 
hyperglycemia.(4) The high blood sugar produces the 
symptoms of frequent urination, increased thirst, 
excessive hunger etc. The mortality rate due to 
Diabetes is high and is ranked 5th among the ten major 
causes of death in India. Globally as of 2013, an 
estimated 382 million people have diabetes worldwide, 
with type2 diabetes making up about 90% of the 
cases.[5] The rising prevalence of DM is adults globally 
estimated to be 150 million and figured to be double by 
2025[6]. Although the prevalence of type1 and type 2 
DM is increasing worldwide, but the prevalence of type 
2 DM is expected to increase more rapidly in future 
because of increasing obesity and reduced physical 
activity. The modern concept of DM implicates the 
impairment of carbohydrates (Kapha) and fat (Meda), 
and protein (Mamsa) metabolism. The classical 
description had not touched the concept of insulin, but 
they have wider concept of Agni which includes all 
enzymes and hormones responsible for all the 
metabolic activities of the body. Moreover implication 
of insulin in DM has not fully succeeded in clearing the 
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doubts. Hence all Pramehas (including Madhumeha) 
can be considered metabolic disorder manifested as 
physical abnormalities of urine. In spite of tremendous 
advancement of modern system of medicine i.e., oral 
hypoglycemic agent and insulin, till date there is no 
such curative remedies owing to its complexity. And 
still scientists are struggling to search an effective and 
harmless therapy. So to have a safe and effective 
Medicare for a long term use, Phalatrikadi Kwath[7], 
reverses or breaks the Samprapti is ideal for the 
particular disease. It is evident that the total effect of all 
the 6 ingredients in case of the formulation rather than 
the action of individual drugs plays a vital role in the 
therapeutics; the drugs in this formulation have anti 
diabetic properties as well as having Kaphahara, 
Pittahara and Medohara properties hence helpful in the 
Samprapti Vighatana of the disease. So to get a better 
management in patients of Madhumeha by palliative 
management, this clinical study is planned. 
AIMS AND OBJECTIVES 
 A comparative, placebo control clinical 
evaluation of Phalatrikadi Kwath in Madhumeha with 
special reference to Diabetes Mellitus Type 2. 
MATERIALS & METHODS 
Plan Protocol: Present study was done in 50 number 
of patients suffering from Madhumeha (DM Type2) 
were selected from the OPD of Gopabandhu Ayurveda 
Mahavidyalaya and Hospital, following the selection 
criteria’s were finally enrolled in the study after 
thorough baseline screening. Informed consent was 
taken from the patient before including them in the 
trial. viz. Patients were selected respective of duration 
of disease (not more than 1 years chronicity) and 
therapeutic status as per the plan protocol and 
excluding criteria. All the 50 patients were divided into 
three groups randomly Group I: - 30 patients were 
treated with Trial drug (Phalatrikadi Kwath) in a dose 
of 50ml twice daily 1/2hr before principal meal. (in 
12hrs interval) with 1gm of Haridra Churna (Turmeric 
powder) and 10ml of Madhu (Honey). Group II: 10 
patients were treated with Control drug (metformin)- 1 
tab (500mg) twice daily 1/2hr before principal meal 
(in 12hrs interval) Group III: 10 patients were treated 
with placebo in a dose of 50ml twice daily 1/2hr before 
principal meals (in 12hrs interval) with 1gm of Haridra 
Churna (Turmeric powder) and 10ml of honey. All the 
above 50 patients were advised with recommended 
classical diet regimen. The patients were registered and 
their data for demographic and clinical profile was 
maintained. 
Duration: 1 month. 
Type of Study: Double blind control clinical trial. 
Trial Drug Review 
Formulation of Phalatrikadi kwath 
The Kwath containing six drugs Fruit of 
Haritaki (Terminalia Chebula), Bibhitaki (Terminalia 
bellarica), Amalaki (Emblica officinalis), Root of Musta 
(Cyperus rotundus), Stem of Daruharidra (Berberis 
aristata), and Root of Indrayaan mula (Citrullus 
colocynthis), were taken in equal quantity[7]. All the 
individual drugs were checked for their safety profile in 
identity, quality and quantity. The individual drugs 
were mixed and subjected to size reduction in a 
pulverize to get coarse powder. The coarse powder 
(Kwatha Churna) of 25gm was packed and the 14 
packets are sealed in a single pack. This pack can be 
used for a week. The medicine was dispensed for 30 
days to all patients and advised to report after 15 days 
interval and noted the nature of frequency and other 
symptoms of the disease. 
Table 1: Diet and lifestyle modification[8] 
Aahara  Name of Pathya Ahara (Advisable) Apathya Ahara(non advisable) 
Cereals Old barley, wheat, rice New rice, wheat 
Pulses Old Moong Dal New Urad dal, Rajma, kabuli chana 
Vegetables Bitter guard, brinjal, carrot, Lauki Potato, sea foods, cabbage, Arbi 
Fruits Jamun, guava, Amla some dry fruits like 
almond, walnut 
Fruits having high sugar content, cashew nut, 
resins 
Liquids Luke warm water, Triphala water, Amla 
juice 
All types of cold & sweet drinks 
Oils Mustard, flax seed Ground nut oil, Til oil 
Milk & Milk 
products 
Double toned milk Full cream milk, curd ghee, cheese 
Physical Exercise 
The disease Prameha disappear quickly by use 
of various physical exercises including Yogasanas, 
massage, anointing, bathing and sprinkling with the 
infusion of some drugs like Vijayasara. Khadira Sara 
also anointing the paste of Ushira, Dalchini, Ela, Aguru, 
Chandan etc destroys the disease at an early date 
otherwise accepting these procedures daily prevents 
the person being affected from the disease. [7] different 
types of physical exercises, walking, jogging were 
advised to do regularly according to the age, gender 
and body built. 
Follow up: The patients were followed- up once in 15 
days up to 1 month. 
Laboratory Investigations: Blood sugar level was 
tested in FBS, PPBS was tested for presence of sugar. 
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The above mentioned laboratory investigations were 
carried out before and after treatment. 
Study Sample- Patients of either gender between 30-
60 years of either age, satisfying the inclusion criteria 
were enrolled for the clinical trial. 
Study Settings: All the patients attending the OPD of 
G.A.M. & Hospital, Puri & were selected for the study. 
Trial was started on march 2014 and completed on 
April 2015. Informed consent was taken from the 
patients before including them in the trial. The selected 
patients were categorized randomly. 
Diagnostic Criteria: Diagnosis was made on the basis 
of classical features of Prameha with elevated blood 
sugar level. 
Inclusion Criteria 
 Willing to give consent to participate in the study. 
 Age Group limit -30-60 years 
 Sex- Both male and female 
 Type of disease- Madhumeha (DM Type2) 
 Fasting blood sugar range- 126mg/dl-180mg/dl 
 Post Prandial blood sugar range- 200mg/dl-
250mg 
 Recently diagnosed not more than 1 year 
chronicity. 
Exclusion criteria 
 DM type1 
 Patients with severe grade blood glucose levels 
 Madhumeha (DM type 2) patients with 
complications like Nephropathy, Neuropathy, and 
Retinopathy 
 Patients with any other chronic disease that 
would interfere with the clinical study. 
 Atherosclerosis, pregnancy, pyrexia, UTI, diabetic 
coma 
 Thyroid disorders 
 lactating mothers 
 Any other current acute illness 
 Patient not willing to participate in the study or 
not in a position to give consent. 
Clinical features 
Subjective  
 Pipasa Adhikyata (Polydipsia)  
 Khudha Adhikyata (Polyphagia) 
 Alasyata (Lethargy) 
 Atisweda (Excessive perspiration ) 
 Karapada daha (Burning sensation in palms and 
soles) 
 Karapada suptata (Numbness in palms and soles) 
 Dourbalya (Weakness) 
 Kandu (Itching)  
 Nidraadhikyata (Excessive sleep) 
 Pindikavestanam (Cramping in legs) 
Objective  
 Avila Mutrata (turbidity of urine) 
 Prabhuta Mutrata (excessive urination) 
 Assessment of the condition will be done based 
on detailed Performa adopting standard scoring 
methods of subjective & objective parameters & will be 
analyzed statistically. 
Statistical Assessment of Result 
 The mean value ± standard deviation (S.D) of 
different sign and symptoms before treatment was 
compared with mean ± S.D after 15th (A.T1) and 30th 
days (A.T2) of treatment. For the purpose of the test of 
significance I have used unpaired ‘t’ test of significance. 
The effectiveness of the trial drug, Control drug, 
Placebo was assessed through the ‘P’ value. 
Severity Assessment Scales 
 For the purpose of the assessment of results I 
have used some grade points taking into consideration 
the different sign and symptoms as follows. 
Severity Grade points 
Highly severe (++++) G4 
Severe (+++) G3 
Moderate (++) G2 
Mild (+) G1 
No sign/symptoms (-) G0 
 Alike other sign and symptoms polyurea, 
fasting blood sugar (FBS), and Post prandial blood 
sugar (PPBS) values were converted into range and 
grades for statistical analysis, thus given below. 
1) Prabhuta Mutrata (Polyuria)  
Frequency of urine 
0 : 3 – 6 times per day, no or rarely at night 
1 : 7 – 10 times per day, 1 – 2 times per night 
2 : 11– 14times per day, 3 – 4 times per night 
3 : > 15 times per day, > 4 times per night 
2) Pipasa - Adhika (Polydipsia) 
0 : Feeling of thirst 5– 6 times/24 hours 
1 : Feeling of thirst 7- 8 times/24 hours 
2 : Feeling of thirst 9 – 10 times/24 hours 
3 : Feeling of thirst 11-12 times/24 hours 
4 : Feeling of thirst 13-14 times/24 hours 
3) Avila Mutrata (Turbidity in urine) 
0 : Crystal clear fluid 
1 : Faintly cloudy or hazy with slight turbidity. 
2 : Turbidity clearly present and newsprint 
easily read through test tube 
3 : Newsprint not easily read through test tube 
4 : Newsprint cannot be visualized through test 
tube 
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4) Kshudha- Adhika ( Appetite) 
0 : As usual / routine ( 0-1 meals)   
1 : Slightly increased (2 – 3meals) 
2 : Moderately increased (4 – 5 meals ) 
3 : Markedly increased (6 – 7 meals)   
5) Kara-Pada Suptata  
0 : No Suptata 
1 : Kara-Pada Suptata incontinuous   
2 : Kara-Pada Suptata continuous but bearable 
& not severe 
3 : Kara-Pada Suptata severe & unbearable 
6) Swedadhikya (Perspiration) 
0 : Sweating after some strenuous or heavy work 
 or in hot & humid weather 
1 : Profuse sweating after moderate work and 
movement 
2 : Sweating after little extra work than routine 
and movement 
3 : Profuse sweating after routine work   
4 : Sweating even at rest or in cold climate 
7) Daurbalya (Weakness) 
0 : Can do routine exercise/work 
1 : Can do moderate exercise with hesitancy 
2 : Can do mild exercise only, with difficulty 
3 : Cannot do mild exercise too 
8) Alasya/Utsahahani (General Debility) 
0 : No Alasya (doing satisfactory work with 
proper vigor and in time)  
1 : Doing satisfactory work with late initiation, 
likes to stand in comparison to walk  
2 : Doing unsatisfactory work with late 
initiation, likes to sit in comparison to stand 
3 : Doing unsatisfactory work with very late  
initiation, likes to lie down in comparison to 
sit. 
4 : Does not want to do work with no initiation,  
likes to sleep in comparison to lie down   
9) Nidradhikya (Sleep) 
0 : Normal & sound sleep for 6 – 8 hrs. /24 hrs. 
with feeling of lightness 
1 : Sleep> 8 -9 hrs. /24 hrs. with slight heaviness 
in the body.   
2 : Sleep >9- 10 hrs. /24 hrs. with heaviness in 
the body associated with Jrimbha. 
3 : Sleep >10 hrs. /24 hrs. with heaviness in the 
body associated with Jrimbha & Tandra   
10) Pindikodveshtana (Cramps) 
0 : No cramps   
1 : Cramps after walking more than 1 km.  
2 : Cramps after walking ½ km 
3 : Inability in walking even ½ km 
11) Fasting blood sugar (mg/dl) 
0 : <126   
1 : 127- 142  
2 : 143- 158 
3 : 159-174 
4 : 175- 190 
12) Postprandial blood sugar (mg/dl)  
0 : < 200 
1 : 201 – 216 
2 : 217 – 232 
3 : 233 – 348 
4 : 249 – 264 
Biochemical Assessment 
 It was done by assessing change in blood sugar 
level in fasting and postprandial state before and after 
treatment. 
Observation and Result 
In this study, out of total 50 enrolled patients 
were enrolled who were between the age of 30-60 
years it was observed that 37 (74%) were found in the 
age group of 40-60 years in which males (62%) are 
more prone to the disease than females. Which 
supports to the statement and corroborates with the 
outcome of the research reference that Diabetes 
Mellitus is a disease of middle age group which is also 
prone to weight gain and now a days to overcome 
social burdens one has to bear utmost stress and 
monotonous food which favors for the disease 
condition? As regards to occupation, higher incidence 
among the sedentary habits (50%) was observed than 
the physically active individuals. Thus observation 
bears striking with the verse of authentic text books 
that Swapna Sukham and Asaya Sukham (sedentary 
habits) is a major causative factor for the disease. In 
consideration to socio economic status it has been 
observed that the maximum cases i.e., middle class, 
56% and higher economic class 36% people are more 
prone to the disease due to under the utmost stress & 
strain both socially and economically which is a 
predisposing factor of Madhumeha.  
 Table 2: Showing the pattern of causative factor (Nidan) in patients of Madhumeha (n=50) 
S.No. Nidan (causative factor) No. of patients percentage 
1 Asayasukham (enjoying long sitting) 41 82 % 
2 Swapnasukham (enjoying long sleeping) 09 18 % 
3 Dadhi Sevan (taking curd) 23 23% 
4 Gramya, Anupa, Udaka Mamsa sevan (meat) 18 36% 
5 Paya(Milk and milk products) 33 66% 
6 Navanna (>1 year old cereals) 09 18% 
7 Guda vikar (jagerry and its products) 09 18% 
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On analyzing the Nidan sevan, habit of enjoying long sitting was found to be present in 82% patients, while 
taking milk & its products etc in 66% of patients, eating Mamsa (flesh) was found in 66% of patients, eating of curd 
was found in 23% of patients and 18% was found in the patients who were taking jagerry products, Navanna and 
enjoying sleeping habits. 
Table 3: Showing the incidence of clinical sign and symptoms among 50 Madhumeha patient 
Signs & Symptoms  N=30 
 Gr-I 
 N=10 
 Gr-II  
 N=10 
 Gr-III  
 N=50 
 
F (%) f (%) f (%) f  (%) 
Prabhuta Mutrata 30  100% 10 100% 10  100% 50  100% 
Pipasa Adhikya 14  46.66% 6  60% 1 10% 21  42% 
Khuda Adhikya 28  93.33% 10  100% 7  70% 45  90% 
Avila Mutrata 25  83.33% 10  100% 6  60% 41  82% 
Daha & Suchikidhavat Pida 8  26.66% 4 40% 0 0% 12  24 
Dourbalya 28 93.33% 10 100% 7 70% 45 90% 
Kara- pada Suptata 16 53.3% 3 30% 3 30% 22 44% 
Utsahahani/ Alasyata 24 80% 3 30% 4 40% 35 70% 
Kandu  7 23.3% 5 50% 0 0% 13 26% 
Pindikaveshtam 24 80% 10 100% 10 100% 44 88% 
Nidradhikya 18 60% 2 20% 2 20% 22 44% 
Swedadhikya 3 10% 6 60% 0 0% 9 18% 
FBS 30 100% 10 100% 10 100% 50 100% 
PPBS 30 100% 10 100% 10 100% 50 100% 
Table 4: Showing the percentages of the patient got improvement (on totality) of different sign and 
symptoms after treatment 
Signs & 
Symptom 
 AT1   AT2 
Group-I Group-II Group-III Group-I Group-II Group-III 
Prabhuta mutrata 100% 90% 90% 100% 100% 100% 
Dourbalya 85.71% 80% 71.43% 100% 90% 100% 
Pindikaveshtam 79.16% 100% 70% 100% 100% 100% 
Pipasa adhikyata 95.65% 100% 66.66% 100% 100% 100% 
FBS 100% 100% 100% 100% 100% 100% 
PPBS 100% 100% 100% 100% 100% 100% 
Table 5: Showing the percentages of change (improvement) to the sign & symptoms after treatment 
Signs & Symptoms 
AT1(%) AT2(%) 
Group-I Group-II Group-III Group-I Group-II Group-III 
Prabhuta mutrata 26.62 18.75 26.86 54.19 52.77 54.48 
Dourbalya 42.37 42.10 27.78 74.58 73.68 55.55 
Pindikaveshtam 41.30 30 --- 84.78 60 --- 
Pipasa adhikyata 64.90 62.50 50 94.34 81.25 75 
FBS 10.24 10.94 4.36 19.55 20.36 15.73 
PPBS 9.25 5.70 4.16 16.66 12.55 7.92 
%=percentage Change 
Table 6: Showing the Clinical Assessment of the Result 
Clinical Assessment 
After 15 days of treatment After 30 days of treatment 
Group I Group II Group III Group I Group II Group III 
f % F % f % f % f % f % 
100% (Cure) 0 Nil 0 Nil 0 Nil 3 10 3 30 0 Nil 
75-99% (Max. improved) 0 Nil 1 10 0 Nil 21 70 7 70 0 Nil 
50-74% (Mod. improved) 18 60 6 60 0 Nil 7 23.33 0 Nil 2 20 
25-49% (Mild. improved) 11 36 3 30 2 20 0 Nil 0 Nil 8 80 
<25% (Unsatisfactory) 1 3.33 0 Nil 8 80 0 Nil 0 Nil 0 Nil 
 Above clinical assessment has been made 
basing on the sign and symptoms along with two 
cardinals laboratory investigation. The percentage of 
results obtained was made into range and described 
below. Clinical assessment of the result shows that, 
after 15days of treatment 3.33% of Group I, 80% in 
Group II got unsatisfactory result, 36% in Group I, 30% 
in Group II and 20% in Group III got mild improvement, 
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60% in both Group I & II got moderate improvement, 
10% in Group II got maximum improvement and no 
one in all the three groups got totally cure. But after 30 
days of treatment, 80% in Group III got mild 
improvement, 23.33% in Group I and 20% in Group III 
got moderate improvement,70% in both Group I & II 
got maximum improvement and only 10% in Group I 
and 30% in Group II got totally cure.  
Table 7: Statistical Analysis Showing the Effectiveness of the Group-I (30 Patients), Group-II (10 Patients) 





























BT 14.73±1.2  29    
AT1 10.96±2.22 14.71 <0.001  *** 
AT2 06.73±1.79 26.39 <0.001  ***  
 
GROUP-II 
BT 15.60±3.06 9    
AT1 10.10±1.73 9.15 <0.001  *** 
AT2 05.90±0.99 11.15 <0.001  *** 
 
GROUP-III 
BT 14.20±1.61 9    
AT1 11.80±1.87 7.9 <0.001  *** 











BT 02.10±0.49 27    
AT1 01.2±0.46 7.63 <0.001  *** 
AT2  0.78 ±0.56 14.72 <0.001  *** 
 
GROUP-II 
BT  01.9 ±0.73 9    
AT1  01.1 ±0.56 6.02 <0.001 *** 
AT2  0.30 ±0.48 9.92 <0.001 *** 
 
GROUP-III 
BT  2.57 ±0.53 6    
AT1  1.85 ±0.37 3.91 <0.01 ** 










BT  2.00 ±0.72 23    
AT1  1.37 ±0.82  9.43 <0.001 *** 
AT2  0.70 ±0.55 11.49 <0.001 *** 
 
GROUP-II 
BT  2.00±0.81 9    
AT1 1.2 ±0.63 6.32 <0.001 *** 
AT2  0.4± 0.51 10.11 <0.001 *** 
 
GROUP-III 
BT 2.1 ±0.56  
9 
   
AT1  1.5±0.52 3.72 <0.01 ** 











GROUP-I BT 2.21 ±1.27 22    
AT1 0.53±0.75  3.60 <0.001 *** 
AT2 0.30±0.55   7.04 <0.001 *** 
 
GROUP-II 
BT  1.18±0.59 7    
AT1  0.5±0.46  7.69 <0.001 *** 
AT2  0.06±0.17  5.46 <0.001 *** 
 
GROUP-III 
BT  0.85±0.47 9    
AT1  0.6±0.21  2.25 <0.05 # 






BT 167.7± 12.44 29    
AT1  132.27±7.94 30.80 <0.001 *** 
AT2 101.43±13.09 21.60 <0.001 *** 
 
GROUP-II 
BT 167 ±12.61 9    
AT1  118.3±13.58 17.32 <0.001 *** 
AT2  88.8±7.23 14.72 <0.001 *** 
 
GROUP-III 
BT  166.2±11.55 9    
AT1  154.3±13.82 8.69 <0.001 *** 






BT 237.23±18.23 29    
AT1  202.8±14.08 18.78 <0.001 *** 
AT2  177.36±9.60 20.71 <0.001 *** 
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S  
GROUP-II 
BT  247.6±15.77 9    
AT1 192.2 ±28.74 5.07 <0.001 *** 
AT2  174.1±4.99 13.58 <0.001 *** 
 
GROUP-III 
BT 237.7 ±17.23 9    
AT1 228 ±16.15 17.42 <0.001 *** 
AT2  214.8±13.13 9.65 <0.001 *** 
From the above table it is revealed that 
unpaired test of significance shows that the 
effectiveness of trial drug as compared to control drug 
& placebo after 30 days of treatment in case of 
polyurea and FBS is highly significant with p value 
0.001, where as in case of weakness, muscle cramps 
and polydipsia is insignificant with p value> 0.05 and in 
case of PPBS the result is significant with (p 
value<0.01). 
DISCUSSION 
Madhumeha is a widely evidential disease 
since ancient age till today and evidence is increasing 
day by day with lips and bound with their 
complications and complexes. It is known as diabetes 
mellitus in modern medicine which is a metabolic 
disorder having a deep relation with diet and lifestyle 
habits. The chronic nature of diabetes and its tendency 
to affect various organs and damages the organs very 
slowly and on average reduces the life span of the 
patient by a decade. It has been appropriately termed 
as “silent killer” and some people call it ‘a disease of 
complications’. The prevalence of this dreadful disease 
is almost increased due to the incorporation of fast 
food, junk food, lack of physical activity etc. it is no 
longer considered as a disease of rich rather it has been 
rapidly in increasing among the poor, in the urban slum 
dwellers, middle class group and even in the rural 
areas. It may be due to rapid changes in the physical 
activity and the dietary habits even among the poorer 
sections of the society. Significant improvement was 
observed following 1 month of administration of drugs 
in all assessment parameters of Prameha. The trial drug 
is indicated in all types of Prameha(7). Prameha is 
caused by vitiation of all the three Dosasa, i.e Vata. Pitta 
and Kapha along with ten Dusyas they are Meda, Rakta, 
Sukra, Jala, Vasa, Lasika, Majja, Rasa, Oja and Mamsa.(10) 
In its clinical feature there is increase in amount and 
frequency of abnormal urine. The main cause given for 
Prameha mainly are sedentary lifestyle and abnormal 
food habits which is responsible for the formation of 
Aama in the body. This Aama reduces the digestive 
power and vitiates the three Dosas in the body. This 
Aama produces Aalasyata, Tandra, Hridaya Vishudhi, 
Dosha Pravritti, Akulmutrata, Guru Udaratva, Aruchi, 
Suptata[11]. Also if we analyze the pathogenesis in 
modern point of view there is two types of mechanism 
responsible for the DM, that is insulin resistant and 
another is pancreatic beta cell failure. In both these 
causes, target tissue defect and deposition of amyloid 
body are found as the main cause. These amyloid body 
are found as the main cause. These amyloid bodies 
deposit on the tissues and disrupt them physically by 
coating the channels thus causing insulin resistance(11). 
These amyloid bodies are also responsible for 
apoptosis of the islet cells by two mechanisms, first by 
calcium deregulation and second is mitochondrial 
dysfunction in the beta cells.[12] 
As regarding the trial drug i.e., Phalatrikadi 
Kwath, the 6 drugs present in it acts on the basic 
pathology of Prameha. The Triphala (Haritaki, 
Bibhitaki, Amalaki) is Kaphapitta Samak, Prameha 
Nasak, Deepan etc. Triphala is having Rasayan 
property[13]. It enhances free radicals and reduce 
oxidative stress and alleviate diabetic complications[19]. 
The methanolic extract of Triphala inhibit lipid 
peroxide formation and to scavenge hydroxyl and 
superoxide radicals in vitro and oral administration of 
the extract reduced the blood sugar levels in normal 
and alloxan diabetic rats.[14] 
Daruharidra (Berberis artistata) root extract 
also have potential anti hyperglycemic and antioxidant 
effect that was found in a study done in CSIR, 
Lucknow[15].The extract of Daruharidra has strong 
potential to regulate glucose homeostasis through 
decreases gluconeogenesis and oxidative stress. The 
roots of Indrayaan Mula (Citrullus colocynthis) have 
hypoglycemic effect. As well as insulin tropic action in 
alloxan induced diabetic rats. Musta (Cyperus rotundus) 
have anti diabetic effect and was found in a study that it 
significantly lowers the blood sugar levels. This 
antihyperglycemic activity can be attributed to its 
antioxidant activity as it showed the strong DPPH 
radical scavenging action in vitro[17]. Mustak is well 
known Amapachak & Deepan[9]. 
The trial drug is considered to be fit for easy 
administration having no side effect. Inspite of its bitter 
and astringent taste it was well tolerated accepted & 
accomplish by the patients. 
Physiochemical analysis demonstrated that the 
PH is favorable for early absorption in stomach as it 
remains acidic. Moreover the qualitative test reveals 
that the Kwath contains tannins, steroids. Alkaloids in 
abundant. Recently tannins have received considerable 
attention as health promoting component in various 
plant foods and several studies have reported on its 
nutraceutical properties, the candebsed tannin extracts 
showed promising antidiabeteic effects.[18] 
  Thus along with the trial drug, the rigid dietary 
restriction and suitable physical exercise programme 
helps at maximum levels. The observation recorded in 
the present study suggest that though the trial drug 
possess hypoglycemic activity and treats the basic 
pathology of type2 DM and further additional studies 
may be performed on this formulation to reduce the 
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over load of the medicine & to overcome the side 
effects of modern medicine. 
CONCLUSION 
  Madhumeha is caused due to Sedentary life 
style, increased stress and strain, and inclusion of junk 
and high calorie diet. The causative factor of Prameha 
reduces the digestive power and promotes the 
formation of Aama (undigested substances) which is 
responsible for the vitiation of all the three Doshas. The 
study confirms in the pathogenesis of the disease that 
there is dominancy of Kapha Dosha, Medo Dusti, 
Rasavaha and Medovaha Srotodusti. The study confirms 
that Phalatrikadi Kwath is effective in treatment of 
Madhumeha as it has the property of Aama Pachana. 
Along with this Kwath the Pathya and apathy are 
equally important in controlling diabetes. People 
between the age group of 40-60 are more prone to the 
disease so they should be aware of the causative factors 
of the disease with its Pathya Apathya. Thus 
Phalatrikadi Kwath treats the basic pathology of type 2 
DM and definitely reduces the symptoms of the illness 
that include polyurea, weakness, muscle cramps, 
polydipsia, FBS and PPBS. 
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